Welcome to our dedicated page for Sana Biotechnology SEC filings (Ticker: SANA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sana Biotechnology’s engineered-cell breakthroughs are exciting—yet their regulatory filings can feel like advanced immunology textbooks. Clinical trial updates, gene-editing methods and cash-runway calculations are scattered across hundreds of pages, leaving analysts asking how to extract the essentials before the market moves.
Stock Titan solves that problem. Our AI reads every Sana Biotechnology quarterly earnings report 10-Q filing and annual report 10-K simplified, then delivers plain-English takeaways on pipeline progress and balance-sheet strength. Need real-time alerts? We push Sana Biotechnology Form 4 insider transactions real-time so you can track executive stock transactions Form 4 the moment they post. From a sudden 8-K material events explained to a detailed proxy statement executive compensation table, we keep the entire library—10-K, 10-Q, 8-K, S-1, DEF 14A—updated within minutes of hitting EDGAR.
Whether you’re monitoring Sana Biotechnology insider trading Form 4 transactions for confidence signals, comparing R&D spend through Sana Biotechnology earnings report filing analysis, or simply understanding Sana Biotechnology SEC documents with AI, our platform turns technical language into actionable context. Find every HIP platform disclosure, follow funding milestones, and answer natural questions like “Sana Biotechnology SEC filings explained simply” without wading through PDFs. Critical biotech data, delivered clearly—so you can focus on decisions, not document hunts.
Sana Biotechnology, Inc. officer Susan D. Wyrick reported activity in company stock. On December 13, 2025, 3,400 restricted stock units vested and converted into common stock at a price of $0.00 per share, increasing her directly held shares. On December 15, 2025, she disposed of 873 shares at $5.22 per share, after which she held 180,790 shares of common stock directly. The filing notes that the restricted stock unit award vested in full on December 13, 2025 and identifies Wyrick as Acting Chief Financial Officer and Principal Accounting Officer.
Sana Biotechnology reported Q3 2025 results, highlighting lower operating expenses and a narrower loss. Total operating expenses were $43.5 million, down from $61.8 million a year ago, driven by research and development of $30.1 million and general and administrative of $10.3 million. Net loss was $42.2 million (basic and diluted net loss per share $0.16), improving from $59.9 million in Q3 2024.
Cash, cash equivalents, and marketable securities totaled $153.1 million as of September 30, 2025. The company completed an August underwritten offering for net proceeds of approximately $80.6 million and sold 7.3 million shares under an ATM for $28.6 million in Q3. Management states existing liquidity, together with these proceeds, will fund planned operations for at least one year from the filing. For the first nine months, operating cash outflow was $111.2 million; results include a non-cash impairment of $44.6 million recognized in Q2 tied to facilities in Bothell and Seattle. Stockholders’ equity was $195.3 million. Shares outstanding were 266,366,120 as of October 29, 2025.
Sana Biotechnology furnished a press release announcing financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The information was furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities or automatically incorporated by reference.
Insider acquisition recorded for Sana Biotechnology (SANA). A Form 4 filed for director Hans Edgar Bishop shows an acquisition on
Sana Biotechnology reported continued development-stage losses and significant balance sheet changes through June 30, 2025. The company recorded a six-month net loss of $143.2 million and a three-month loss of $93.8 million, driven in part by a $44.6 million non-cash impairment of long-lived assets related to its Bothell and Seattle facilities. Total assets fell to $361.6 million from $501.0 million at year-end, and cash and cash equivalents declined to $71.3 million on the balance sheet. Long-term liabilities include $117.1 million of contingent consideration and $8.6 million of success payment liabilities tied to prior acquisitions and license agreements. Management completed an ATM facility and, subsequently, an underwritten offering that together provided additional net proceeds (including $70.0 million from the August offering and $28.6 million raised under the ATM after June 30), and believes available liquidity plus those proceeds will fund planned operations for at least one year. The company reported positive clinical signals for an investigator-sponsored islet transplant (UP421), including C-peptide production and PET-MRI evidence of engraftment, and announced portfolio prioritization toward T1D, B-cell autoimmune diseases, refractory B-cell malignancies, and the fusogen platform.
Sana Biotechnology announced it has issued a press release reporting its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Form 8-K. The company states the press release is being furnished and not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless explicitly stated. The 8-K lists Exhibit 99.1 and an Inline XBRL cover page, identifies the registrant as an emerging growth company, and is signed by Acting Chief Financial Officer Susan Wyrick. The company trades on Nasdaq under the ticker SANA.
On 6-Aug-2025 Sana Biotechnology, Inc. (SANA) executed an Underwriting Agreement with Morgan Stanley, Goldman Sachs and BofA to raise capital through a public offering.
- Securities: 20,895,522 common shares at $3.35 and 1,492,537 pre-funded warrants at $3.3499 per underlying share.
- Underwriter purchase price: $3.149 per share and $3.1489 per warrant.
- Greenshoe: 30-day option for up to 3,358,208 additional shares.
- Net proceeds: ≈$70 million to SANA, assuming no option exercise and after fees.
- Closing: expected 8-Aug-2025, subject to customary conditions.
- Warrant terms: $0.0001 exercise price, no expiration, 4.99 % ownership cap (adjustable to ≤19.99 %), cash or cashless exercise, standard anti-dilution and Fundamental Transaction protections.
The raise is being made from shelf registration statement No. 333-277584. All securities are issued by the company, providing immediate liquidity while increasing the share count and potential future dilution.
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
What is the market cap of Sana Biotechnology (SANA)?
